Attached files
| file | filename |
|---|---|
| 10-K - 10-K 2020 - Ovid Therapeutics Inc. | ovid-10k_20201231.htm |
| EX-32.1 - EX-32.1 - Ovid Therapeutics Inc. | ovid-ex321_13.htm |
| EX-31.2 - EX-31.2 - Ovid Therapeutics Inc. | ovid-ex312_9.htm |
| EX-31.1 - EX-31.1 - Ovid Therapeutics Inc. | ovid-ex311_11.htm |
| EX-10.25 - EX-10.25 - Ovid Therapeutics Inc. | ovid-ex1025_869.htm |
| EX-10.19 - EX-10.19 - Ovid Therapeutics Inc. | ovid-ex1019_727.htm |
| EX-10.18 - EX-10.18 - Ovid Therapeutics Inc. | ovid-ex1018_728.htm |
| EX-10.17 - EX-10.17 - Ovid Therapeutics Inc. | ovid-ex1017_726.htm |
Consent of Independent Registered Public Accounting Firm
To Board of Directors
Ovid Therapeutics Inc.:
We consent to the incorporation by reference in the registration statements (Nos. 333-218167, 333-224033, 333-233101, and 333-237098) on Form S-8 and (No. 333-250054) on Form S-3 of Ovid Therapeutics Inc. of our report dated March 15, 2021, with respect to the consolidated balance sheets of Ovid Therapeutics Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, changes in stockholders’ equity, and cash flows for the years then ended, and the related notes, which report appears in the December 31, 2020 annual report on Form 10-K of Ovid Therapeutics Inc.
/s/ KPMG LLP
New York, New York
March 15, 2021